Loewen Andrea's Form 4 filing
Reata Pharmaceuticals Inc (RETA) · filed Mar 6, 2023
- Accession no.
- 0001209191-23-016327
- Filed
- Mar 6, 2023
- Trade date
- Mar 2-3, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $160.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Loewen AndreaCIK 0001591100 | Officer (SVP, Global Regulatory Affairs) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −218 | $90.61 | −$19,752.98 | 44,394 | Direct | |
| Mar 3, 2023 | Class A common stock | SSaleDisposed | −1,601 | $87.73 | −$140,455.73 | 42,793 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.